Par Nijhawan

Par Nijhawan

Company: Edesa Biotech

Job title: Chief Executive Officer

Seminars:

Panel Discussion: Considering Early Endpoints in Clinical Trials to Benchmark ARDS Therapeutic Progress & Confidently Prove Proof of Concept 9:15 am

Read more

day: Day One

Evaluating Previous ARDS Preclinical & Clinical Trial Designs to Assess the Optimum Path to Take for Future Studies: TLR4 Inhibitors with a Monoclonal Antibody to Treat ARDS 8:25 am

Highlighting the mechanism of action of EB05, a TLR4 inhibitor Reviewing the components of preclinical study designs which allowed or inhibited progression to the clinic Delving into past clinical trial designs to enable the success of current and future clinical trialsRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.